An anti-PD-1-GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy.
Nature Cancer
Chan, Sarah S; Belmar, Nicole N; Ho, Sun S; Rogers, Bryan B; Stickler, Marcia M; Graham, Michelle M; Lee, Eileen E; Tran, Ninian N; Zhang, Dong D; Gupta, Priyanka P; Sho, Mien M; MacDonough, Tracy T; Woolley, Andrew A; Kim, Han H; Zhang, Hong H; Liu, Wei W; Zheng, Pingping P; Dezso, Zoltan Z; Halliwill, Kyle K; Ceccarelli, Michele M; Rhodes, Susan S; Thakur, Archana A; Forsyth, Charles M CM; Xiong, Mengli M; Tan, Siu Sze SS; Iyer, Ramesh R; Lake, Marc M; Digiammarino, Enrico E; Zhou, Li L; Bigelow, Lance L; Longenecker, Kenton K; Judge, Russell A RA; Liu, Cassie C; Trumble, Max M; Remis, Jonathan P JP; Fox, Melvin M; Cairns, Belinda B; Akamatsu, Yoshiko Y; Hollenbaugh, Diane D; Harding, Fiona F; Alvarez, Hamsell M HM
The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms.
Oncoimmunology
Pazina, Tatiana T; James, Ashley M AM; MacFarlane, Alexander W AW; Bezman, Natalie A NA; Henning, Karla A KA; Bee, Christine C; Graziano, Robert F RF; Robbins, Michael D MD; Cohen, Adam D AD; Campbell, Kerry S KS